Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1505) 1505
Publication (126) 126
Book Review (23) 23
Magazine Article (7) 7
Book Chapter (2) 2
Conference Proceeding (2) 2
Book / eBook (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1316) 1316
male (881) 881
indans - therapeutic use (878) 878
female (744) 744
indans - adverse effects (693) 693
index medicus (677) 677
aged (669) 669
piperidines - therapeutic use (602) 602
donepezil (527) 527
alzheimer disease - drug therapy (486) 486
middle aged (465) 465
cholinesterase inhibitors - therapeutic use (449) 449
piperidines - adverse effects (423) 423
treatment outcome (399) 399
indans - administration & dosage (395) 395
pharmacology & pharmacy (372) 372
double-blind (341) 341
alzheimer's disease (334) 334
cholinesterase inhibitors - adverse effects (323) 323
indans - pharmacology (323) 323
clinical neurology (292) 292
animals (285) 285
dementia (281) 281
double-blind method (280) 280
aged, 80 and over (275) 275
psychiatry (267) 267
adult (264) 264
alzheimers-disease (234) 234
efficacy (229) 229
nootropic agents - therapeutic use (227) 227
rivastigmine (203) 203
dose-response relationship, drug (198) 198
drug therapy (194) 194
neurosciences (191) 191
geriatrics & gerontology (184) 184
piperidines - administration & dosage (182) 182
safety (171) 171
nootropic agents - adverse effects (159) 159
rats (150) 150
piperidines - pharmacology (146) 146
pulmonary disease, chronic obstructive - drug therapy (144) 144
severity of illness index (144) 144
indans - pharmacokinetics (143) 143
cholinesterase inhibitors (140) 140
drug therapy, combination (140) 140
placebo-controlled trial (140) 140
parkinson disease - drug therapy (138) 138
cholinesterase inhibitors - administration & dosage (137) 137
neuropsychological tests (134) 134
cholinesterase inhibitors - pharmacology (130) 130
time factors (127) 127
galantamine - therapeutic use (117) 117
alzheimer disease - psychology (113) 113
quinolones - administration & dosage (112) 112
randomized controlled trials as topic (110) 110
care and treatment (109) 109
parkinson's disease (109) 109
indacaterol (108) 108
drug administration schedule (107) 107
medicine, general & internal (105) 105
analysis (104) 104
research (101) 101
cognition - drug effects (100) 100
alzheimers disease (99) 99
gerontology (98) 98
cholinesterase-inhibitors (95) 95
quinolones - adverse effects (95) 95
respiratory system (94) 94
cognition disorders - drug therapy (93) 93
rasagiline (93) 93
phenylcarbamates - therapeutic use (92) 92
quinolones - therapeutic use (91) 91
galantamine (88) 88
clinical trials (87) 87
clinical trials as topic (87) 87
cognition (86) 86
dementia - drug therapy (85) 85
drug interactions (85) 85
bronchodilator agents - administration & dosage (84) 84
dosage and administration (82) 82
pulmonary disease, chronic obstructive - physiopathology (80) 80
therapy (80) 80
lung diseases, obstructive (78) 78
memantine - therapeutic use (78) 78
copd (76) 76
galantamine - adverse effects (74) 74
tiotropium (73) 73
memantine (72) 72
trial (72) 72
piperidines - pharmacokinetics (71) 71
bronchodilator agents - therapeutic use (70) 70
administration, oral (69) 69
bronchodilator agents - adverse effects (69) 69
mice (69) 69
moderate (68) 68
neuroprotective agents - therapeutic use (68) 68
chronic obstructive pulmonary disease (65) 65
cross-over studies (65) 65
obstructive pulmonary-disease (65) 65
adolescent (64) 64
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1443) 1443
German (16) 16
Spanish (14) 14
Japanese (13) 13
French (12) 12
Danish (4) 4
Chinese (3) 3
Hungarian (2) 2
Dutch (1) 1
Finnish (1) 1
Italian (1) 1
Norwegian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada
by Ali, Thibault B and Schleret, Thomas R and Reilly, Brian M and Chen, Winston Yuchen and Abagyan, Ruben
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0144337
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase... 
RIVASTIGMINE | EFFICACY | SAFETY | ALZHEIMERS-DISEASE | MULTIDISCIPLINARY SCIENCES | PATCH | Indans - adverse effects | Dementia - drug therapy | Rivastigmine - adverse effects | United States | Humans | Alzheimer Disease - drug therapy | Pharmacovigilance | Canada | Piperidines - adverse effects | Cholinesterase Inhibitors - adverse effects | Galantamine - adverse effects | Adverse Drug Reaction Reporting Systems - statistics & numerical data | United States Food and Drug Administration | Databases, Factual | Care and treatment | Databases | Analysis | Patient outcomes | Development and progression | Research | Alzheimer's disease | Vigilance | Statistical analysis | Clinical trials | Pharmacology | FDA approval | Acetylcholinesterase | Cholinesterase inhibitors | Data bases | Cholinesterase | Marketing | Side effects | Online data bases | Medical errors | Inhibitors | Pharmacy | Dementia disorders | Internet | Drug therapy | Product safety | Pharmaceutical sciences | Dementia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
by Kavirajan, Harish, MD and Schneider, Lon S, MD
Lancet Neurology, The, ISSN 1474-4422, 2007, Volume 6, Issue 9, pp. 782 - 792
Summary Background Cholinesterase inhibitors and memantine do not have regulatory approval in most of the world for treatment of vascular dementia. A... 
Neurology | DONEPEZIL | MULTICENTER | GALANTAMINE | ALZHEIMERS-DISEASE | CLINICAL NEUROLOGY | Excitatory Amino Acid Antagonists - therapeutic use | Double-Blind Method | Phenylcarbamates - therapeutic use | Humans | Dementia, Vascular - drug therapy | Drug Evaluation | Treatment Outcome | Indans - therapeutic use | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Databases, Bibliographic - statistics & numerical data | Galantamine - therapeutic use | Time Factors | Piperidines - therapeutic use | Rivastigmine | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Odds Ratio | Complications and side effects | Esterases | Vascular dementia | Cholinesterase inhibitors | Analysis | Smart drugs and nutrients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey
by Vardigan, Joshua D and Cannon, Christopher E and Puri, Vanita and Dancho, Mandy and Koser, AmyJo and Wittmann, Marion and Kuduk, Scott D and Renger, John J and Uslaner, Jason M
Psychopharmacology, ISSN 0033-3158, 6/2015, Volume 232, Issue 11, pp. 1859 - 1866
The standards of care for Alzheimer’s disease, acetylcholinesterase inhibitors such as donepezil (Aricept®), are dose-limited due to adverse side-effects.... 
Neurosciences | Xanomeline | Biomedicine | Muscarinic | Donepezil | Side-effects | Cognition | Pharmacology/Toxicology | Acetylcholinesterase | Psychiatry | Alzheimer’s | Alzheimer's | OBJECT RETRIEVAL | DETOUR | PSYCHIATRY | ALZHEIMERS-DISEASE | BEHAVIORAL SYMPTOMS | NEUROSCIENCES | CHOLINERGIC HYPOTHESIS | ACETYLCHOLINE-RECEPTORS | MEMORY | PHARMACOLOGY & PHARMACY | DEFICITS | GASTROINTESTINAL MOTOR-ACTIVITY | AGONIST | Muscarinic Agonists - pharmacology | Humans | Male | Macaca mulatta | Piperidines - pharmacology | Receptor, Muscarinic M1 - drug effects | Attention - drug effects | Female | Problem Solving - drug effects | Thiadiazoles - pharmacology | Piperidines - toxicity | Quinolizines - toxicity | Salivation - drug effects | Defecation - drug effects | Alzheimer Disease - drug therapy | Quinolizines - pharmacology | Cognition - drug effects | Neuropsychological Tests | Thiadiazoles - toxicity | Orientation - drug effects | Animals | Pyridines - toxicity | Indans - toxicity | Aged | Pyridines - pharmacology | Appetitive Behavior - drug effects | Indans - pharmacology | Research | Drug therapy | Alzheimer's disease | Side effects | Alzheimers disease | Monkeys & apes | Psychopharmacology | Animal cognition
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text An unusual cardiovascular adverse effect of donepezil
by Celik, I.E and Acar, B and Çay, S
Internal Medicine Journal, ISSN 1444-0903, 08/2015, Volume 45, Issue 8, pp. 877 - 878
MEDICINE, GENERAL & INTERNAL | Indans - adverse effects | Arrhythmias, Cardiac - chemically induced | Dementia - drug therapy | Humans | Middle Aged | Piperidines - adverse effects | Cholinesterase Inhibitors - adverse effects | Electrocardiography | Female
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis
by Tan, Chen-Chen
Journal of Alzheimer's disease : JAD, ISSN 1387-2877, 2014, Volume 41, Issue 2, pp. 615 - 631
Background: The role of currently available drugs for Alzheimer's disease (AD) has been controversial, with some national formularies restricting their use,... 
rivastigmine | memantine | safety | donepezil | meta-analysis | systematic review | Alzheimer's disease | galantamine | efficacy | MODERATE | MULTICENTER | GLOBAL FUNCTION | 24-WEEK | NEUROSCIENCES | DOUBLE-BLIND | THERAPIES | PLACEBO-CONTROLLED TRIAL | Indans - adverse effects | Phenylcarbamates - therapeutic use | Humans | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Phenylcarbamates - adverse effects | Nootropic Agents - adverse effects | Indans - therapeutic use | Randomized Controlled Trials as Topic | Cholinesterase Inhibitors - administration & dosage | Galantamine - therapeutic use | Piperidines - therapeutic use | Rivastigmine | Piperidines - adverse effects | Galantamine - adverse effects | Memantine - therapeutic use | Memantine - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Sponging off nature for new drug leads
by Andersen, Raymond J
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 3 - 14
Marine sponges have consistently been the richest source of new marine natural products with unprecedented chemical scaffolds and potent biological activities... 
Porifera | Marine natural products | Drug discovery | ANDROGEN RECEPTOR | INOSITOL 5-PHOSPHATASE | MAST-CELLS | PAPUA-NEW-GUINEA | STRUCTURE ELUCIDATION | MARINE SPONGE | SHIP1 ACTIVATOR AQX-1125 | IN-VIVO | PHARMACOLOGY & PHARMACY | CYSTITIS/BLADDER PAIN SYNDROME | RESISTANT PROSTATE-CANCER | Indans - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Drugs, Investigational - therapeutic use | Antineoplastic Agents - therapeutic use | Prodrugs - chemistry | Nonsteroidal Anti-Androgens - chemistry | Oligopeptides - therapeutic use | Nonsteroidal Anti-Androgens - therapeutic use | Sterols - adverse effects | Glycerol - analogs & derivatives | Porifera - chemistry | Benzhydryl Compounds - therapeutic use | Oligopeptides - chemistry | Anti-Asthmatic Agents - chemistry | Glycerol - therapeutic use | Indans - chemistry | Anti-Asthmatic Agents - pharmacology | Pyrrolidinones - adverse effects | Antimitotic Agents - adverse effects | Pyrrolidinones - therapeutic use | Antimitotic Agents - therapeutic use | Biological Products - isolation & purification | Biological Products - chemistry | Pyrrolidinones - isolation & purification | Cyclohexanols - therapeutic use | Oligopeptides - pharmacology | Anti-Asthmatic Agents - adverse effects | Cyclohexanols - adverse effects | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Oligopeptides - adverse effects | Indans - therapeutic use | Benzhydryl Compounds - chemistry | Drugs, Investigational - chemistry | Sterols - therapeutic use | Benzhydryl Compounds - adverse effects | Antineoplastic Agents - adverse effects | Cyclohexanols - chemistry | Nonsteroidal Anti-Androgens - adverse effects | Drug Design | Antineoplastic Agents - pharmacology | Glycerol - pharmacology | Aquatic Organisms - chemistry | Nonsteroidal Anti-Androgens - pharmacology | Sterols - pharmacology | Sterols - chemistry | Antineoplastic Agents - chemistry | Drug Discovery | Pyrrolidinones - chemistry | Prodrugs - adverse effects | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antimitotic Agents - pharmacology | Benzhydryl Compounds - pharmacology | Prodrugs - therapeutic use | Prodrugs - pharmacology | Antimitotic Agents - chemistry | Chemical oceanography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Tendon rupture as an adverse effect of rasagiline
by Lefaucheur, Romain and Fetter, Damien and Gaillon, Gaëlle and Borden, Alaina and Maltête, David
Clinical Neuropharmacology, ISSN 0362-5664, 2014, Volume 37, Issue 2, pp. 62 - 62
A 66-year-old woman with advanced Parkinson disease (PD) was referred to our center for an adjustment of her antiparkinsonian medication. To reduce daily... 
Parkinson disease | Musculoskeletal pain | Adverse effect | Rasagiline | rasagiline | musculoskeletal pain | adverse effect | PHARMACOLOGY & PHARMACY | CLINICAL NEUROLOGY | PARKINSONS-DISEASE | Indans - adverse effects | Monoamine Oxidase Inhibitors - adverse effects | Rupture, Spontaneous - chemically induced | Humans | Female | Aged | Tendon Injuries - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
by Wedzicha, Jadwiga A and Banerji, Donald and Chapman, Kenneth R and Vestbo, Jørgen and Roche, Nicolas and Ayers, R. Timothy and Thach, Chau and Fogel, Robert and Patalano, Francesco and Vogelmeier, Claus F and FLAME Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
This randomized trial compared a long-acting beta-agonist (LABA) plus a glucocorticoid with a LABA plus a long-acting muscarinic antagonist for preventing... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | EFFICACY | TO-SEVERE COPD | BLOOD EOSINOPHILS | SAFETY | PARALLEL-GROUP | INHALED CORTICOSTEROIDS | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | Glycopyrrolate - adverse effects | Indans - adverse effects | Pulmonary Disease, Chronic Obstructive - mortality | Glucocorticoids - therapeutic use | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Administration, Inhalation | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Fluticasone-Salmeterol Drug Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Indacaterol | Dosage and administration | Salmeterol | Respiratory therapy | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Fluticasone | Preventive medicine | Patients | Inhalation | Obstructive lung disease | Comparative studies | Chronic obstructive pulmonary disease | Pharmaceuticals | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study
by Vogelmeier, Claus F, Prof and Bateman, Eric D, Prof and Pallante, John, BS and Alagappan, Vijay KT, MD and D'Andrea, Peter, MD and Chen, Hungta, PhD and Banerji, Donald, MD
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Summary Background QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease (COPD). It... 
Pulmonary/Respiratory | FORMOTEROL | MANAGEMENT | RESPIRATORY SYSTEM | SALMETEROL/FLUTICASONE PROPIONATE | INHALED CORTICOSTEROIDS | EXACERBATIONS | PREVENTION | TIOTROPIUM | OUTCOMES | COMBINATION | COPD | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Sympathomimetics - administration & dosage | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Indans - therapeutic use | Quinolones - adverse effects | Quinolones - therapeutic use | Female | Indans - administration & dosage | Glucocorticoids - adverse effects | Sympathomimetics - adverse effects | Glycopyrrolate - adverse effects | Sympathomimetics - therapeutic use | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Administration, Inhalation | Albuterol - analogs & derivatives | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Albuterol - therapeutic use | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
by Wilkinson, David, Dr and Windfeld, Kristian, PhD and Colding-Jørgensen, Eskild, MD
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 11, pp. 1092 - 1099
Summary Background In human beings, 5-HT6 receptors are almost exclusively expressed in the brain, particularly in areas relevant for cognition, such as the... 
Neurology | INVENTORY | CLINICAL NEUROLOGY | SB-742457 | Indans - adverse effects | Receptors, Serotonin - physiology | Benzylamines - adverse effects | Follow-Up Studies | Humans | Male | Indans - therapeutic use | Alzheimer Disease - diagnosis | Serotonin Antagonists - adverse effects | Aged, 80 and over | Female | Alzheimer Disease - psychology | Cognition Disorders - psychology | Double-Blind Method | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Serotonin Antagonists - therapeutic use | Treatment Outcome | Cognition Disorders - drug therapy | Nootropic Agents - adverse effects | Cognition Disorders - diagnosis | Indoles - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Indoles - therapeutic use | Aged | Benzylamines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
by Howard, Robert and McShane, Rupert and Lindesay, James and Ritchie, Craig and Baldwin, Ashley and Barber, Robert and Burns, Alistair and Dening, Tom and Findlay, David and Holmes, Clive and Hughes, Alan and Jacoby, Robin and Jones, Roy and Jones, Rob and McKeith, Ian and Macharouthu, Ajay and O'Brien, John and Passmore, Peter and Sheehan, Bart and Juszczak, Edmund and Katona, Cornelius and Hills, Robert and Knapp, Martin and Ballard, Clive and Brown, Richard and Banerjee, Sube and Onions, Caroline and Griffin, Mary and Adams, Jessica and Gray, Richard and Johnson, Tony and Bentham, Peter and Phillips, Patrick
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 10, pp. 893 - 903
In patients with moderate or severe Alzheimer's disease receiving donepezil, those assigned to continue donepezil had less cognitive decline than did those... 
POPULATION | MEDICINE, GENERAL & INTERNAL | DEMENTIA | EFFICACY | SAFETY | DOUBLE-BLIND | 24-WEEK | QUALITY-OF-LIFE | CHOLINESTERASE-INHIBITORS | RECEIVING DONEPEZIL | Indans - adverse effects | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Excitatory Amino Acid Antagonists - therapeutic use | Double-Blind Method | Humans | Kaplan-Meier Estimate | Alzheimer Disease - drug therapy | Male | Treatment Outcome | Patient Dropouts | Indans - therapeutic use | Drug Synergism | Piperidines - therapeutic use | Piperidines - adverse effects | Aged, 80 and over | Cholinesterase Inhibitors - adverse effects | Female | Aged | Psychological Tests | Cholinesterase Inhibitors - therapeutic use | Drug Therapy, Combination | Memantine - therapeutic use | Excitatory Amino Acid Antagonists - adverse effects | Memantine - adverse effects | Caregivers | Activities of daily living | Neurodegenerative diseases | Cognitive ability | Clinical trials | Patients | Cholinesterase | Memantine | Cognition & reasoning | Older people | Donepezil | Alzheimers disease | Alzheimer's disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
by Zhong, Nanshan and Wang, Changzheng and Zhou, Xiangdong and Zhang, Nuofu and Humphries, Michael and Wang, Linda and Thach, Chau and Patalano, Francesco and Banerji, Donald and LANTERN Investigators
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights